Member Info for Screech777

Assays on both are extremely close and either one could be a game changer.
Look forward to next week

GLA

Molopo news is due and imo will be a game changer. 1p warrants expire tomorrow, so no more selling pressure.
Take off after tomorrow imo & Haneti and Molopo are going to be huge

GLA

Looks like news coming question is which Molopo or Haneti ?

My moneys on Molopo is going to be a company maker

GLA

Ayatollahblair Molopo update imminent and somebody is happily block buying 500k chunks . 11 projects and takes one good drill result to transform the SP
My bet is on a good RNS landing this week

Imo under 3p is a bargain right now and those who are waiting on the sideline for warrants sell off on the 18th Feb could be in for a surprise
Molopo farm update due and based on the previous RNS i think this one could catch a lot of people out. Imo Molopo update could blow the bloody doors off
Molopo news due this week

Gla

Somebody loading up on the cheap before news lands

Great day i think we will see a new TR1 tomorrow 7am tomorrow or intra day

Great finish with the market bidding in size after close in auction. Gap up tomorrow can see another strong day, bags to come here

NT into close bodes well for tomorrow, no speeding ticket needed, justified from the last RNS. Tomorrow should be fun 0.17-0.20 imo

Rumours of a tie up with GSK, it true expect fireworks small mcap could see 20p imo

There is ongoing significant investment by large pharmaceutical companies such as AstraZeneca, GSK, Boehringer Ingelheim and others to develop neutralising therapies for COVID-19,” he added.? “There is significant interest around the world in neutralising therapies for COVID-19 given the uncertainties around the timeline for developing an effective vaccine and deploying it,” said Professor David Bhella, Professor of Structural Virology (Centre for Virus Research) at the University of Glasgow.

In the coming weeks we will launch 2 unique antigen tests, BAMS and mass screening POC saliva based work the Affimers being cheap to make with high specificity. We have also proved it can pretty much work as a vaccine which again demonstrates the versatility and effectiveness of the Affimer platform. So many other applications. Massive news.

Today’s video update

stated (23rd June) that their prototype will be ready by end of June and they're aiming for a "high performance test," which means NPV of 99.9% when used in the general population.

Big big statement.

Imo bams validation this week followed by new partner, large pharmaceutical companies such as AstraZeneca, GSK, Boehringer Ingelheim
Then Cytiva news next week for prototype device with lab data
Very exciting few weeks ahead, expect fireworks soon

Latest video from Avacta, fantastic update
News from Cytiva End of June for prototype device with lab data re accuracy, manufacturing initially in the U.K.

But whilst the market is fixated on the LFT, let’s not forget the dark horse Adeptrix’s BAMS test which imo could become the most accurate Covid-19 test in the world.

Clinical validation began around the 7th June IMO, so news imminent followed shortly after FDA/CE approval

We are now entering a period of rich newsflow and I wouldn’t want to be sitting on the sidelines, expect some big moves soon

Dr Eliot Forster brings more than 25 years of experience in the pharmaceutical and biotechnology industry.

He was most recently chief executive of Immunocore, helping it to raise more than £230m in equity and non-dilutive funding as well as securing partnerships with AstraZeneca and the Bill & Melinda Gates Foundation.

https://www.insidermedia.com/news/yorkshire/new-chairman-appointed-at-avacta-group

Followed by fast tracked FDA/CE approval week after.
Revenues from the test July

In the coming weeks we will launch 2 unique antigen tests, BAMS and mass screening POC saliva based work the Affimers being cheap to make with high specificity. We have also proved it can pretty much work as a vaccine which again demonstrates the versatility and effectiveness of the Affimer platform.

Avacta now appears positioned to reach a major inflection point. Adopted by a large and well resourced partner, a neutralising Affimer therapy could potentially be developed more quickly than a vaccine, for which Avacta considers the likelihood of success to be high.

There is ongoing significant investment by large pharmaceutical companies such as AstraZeneca, GSK, Boehringer Ingelheim and others to develop neutralising therapies for COVID-19,” he added.? “There is significant interest around the world in neutralising therapies for COVID-19 given the uncertainties around the timeline for developing an effective vaccine and deploying it,” said Professor David Bhella, Professor of Structural Virology (Centre for Virus Research) at the University of Glasgow.

Results in 24 hrs, this is where antigen tests are a game changer

AVCT’s type of test could render a a big portion of the PCR market obsolete. Not only do they take a fraction of the time to yield results, but they cost a fraction of the price. Customers of PCR test manufactures like NCYT would just reduce or stop orders, and would start buying the antigen tests in the millions

News very soon

The next step here is to partner up with someone like AstraZenca who can prove up affirmer tech for virus therapies
It’s history in the making if it works = huge Avacta game changer, can see us having a test and a cure. Avacta is going surprise so many people with its ground breaking affirmer tech

Only a matter of time before a licence deal with a huge co like AstaZenca lands

RK i agree with you multiples of the sp incoming soon £10+ by end of August watch this space

All the derampers on here last night shame on you

Courtesy of Myles

Its prototype BAMS test can "detect the coronavirus spike protein... in the concentration range appropriate for a clinical diagnostic test."

In short, the test works. It will very likely be generating revenue for AVCT in July, IMO.

four additional points to note in the RNS.

1) The test is likely to be both highly specific and sensitive. This will be critical in securing major contracts from public health organisations across the world.

2. the BAMS test could be further enhanced to detect other antigens of the virus particle. Besides improving sensitivity, this could be important in tracking mutations.

3) All is going well with #AVCT's #COVID19 LFT. CEO states:

"This bodes well for all our COVID-19 antigen test development programmes."

And

"We continue to make very good progress with Cytiva on the saliva-based antigen test."

Prototype to be

completed shortly IMO, and hopefully also tested in both the US (FDA) and UK/EU (CE Marking).

I expect further distribution partners to be announced shortly.

For the first time, I will also state my belief that #AVCT is developing a third type of test, not yet announced

4) The Adeptrix CEO alludes to the use of #AVCT's Affimer reagents in a #COVID19 neutralising therapy.

A peculiar reference, given it came from Adeptrix's CEO, and not AVCT's. A request from AVCT to promote the concept, or a suggestion that something is being worked one?

For me, this successful development of the BAMS test will now underpin a major chunk of #AVCT's mkt cap (or more than it) throughout H2, regardless of all of its other activities. That is based on the assumption that it could be generating monthly royalties of $10m to $20m.